PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Clinical trial NCT03740893 · RECRUITING
Trial details
- NCT number
- NCT03740893
- Sponsor
- Institute of Cancer Research, United Kingdom
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-15
- Primary completion
- 2026-12-01
- Enrollment
- 119
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.